[Federal Register Volume 62, Number 155 (Tuesday, August 12, 1997)]
[Notices]
[Page 43185]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-21247]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration

    By Notice dated March 12, 1997, and published in the Federal 
Register on March 19, 1997, (62 FR 13169), Glaxo Wellcome Inc., Attn: 
Jeffrey A. Weiss, 1011 North Arendell Avenue, P.O. Box 1217, Zebulon, 
North Carolina 27597-2309, made application to the Drug Enforcement 
Administration to be registered as an importer of remifentanil (9739), 
a basic class of controlled substance listed in Schedule II.
    No comments or objections have been received. DEA has considered 
the factors in Title 21, United States Code, Section 823(a) and 
determined that the registration of Glaxo Wellcome Inc. to import 
remifentanil is consistent with the public interest and with United 
States obligations under international treaties, conventions, or 
protocols in effect on May 1, 1971, at this time. Therefore, pursuant 
to Section 1008(a) of the Controlled Substances Import and Export Act 
and in accordance with Title 21, Code of Federal Regulations, Section 
1301.34, the above firm is granted registration as an importer of the 
basic class of controlled substance listed above.

    Dated: July 28, 1997.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 97-21247 Filed 8-11-97; 8:45 am]
BILLING CODE 4410-09-M